Biomodulatory Treatment of Patients with Castration-Resistant Prostate Cancer: A Phase II Study of Imatinib with Pioglitazone, Etoricoxib, Dexamethasone and Low-Dose Treosulfan
Crossref DOI link: https://doi.org/10.1007/s12307-014-0161-7
Published Online: 2014-12-11
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Vogelhuber, M.
Feyerabend, S.
Stenzl, A.
Suedhoff, T.
Schulze, M.
Huebner, J.
Oberneder, R.
Wieland, W.
Mueller, S.
Eichhorn, F.
Heinzer, H.
Schmidt, K.
Baier, M.
Ruebel, A.
Birkholz, K.
Bakhshandeh-Bath, A.
Andreesen, R.
Herr, W.
Reichle, A.
License valid from 2014-12-11